Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
نویسندگان
چکیده
The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomyoma, and leiomyosarcoma are typically CD117-negative. GIST research and clinical care now represent a paradigm of translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that selectively inhibit etiologic "driver" pathways, leading to dramatically improved clinical outcomes. A series of investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review, we discuss the highlights of recent advances and novel agents for GIST therapy.
منابع مشابه
Synchronous Gastrointestinal Stromal Tumor and Axillary Deep Fibromatosis: A Rare Association
Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and most commonly affects the stomach, while fibromatosis is a rare locally aggressive fibrous tissue neoplasm. There have been reports of GIST and fibromatosis occurring in same individual and in most of them fibromatosis occurs within the abdomen. In 75% of patients fibromatosis occurs aft...
متن کاملThe study of 13 cases of Gastrointestinal stromal tumors in Kerman
13 cases of gastrointestinal stromal tumors (GIST) diagnosed in Kerman university hospitals between 1370-1376 are reviewed.of these cases,6 were male and 7 were female.patients, age ranged between 19 to 70 years with a median of 47.8 years. in 8 cases tumor developed in stomach and in 5 cases it originated from small intestine.all available H & E stained slides were reviewed and PAS and masson...
متن کاملThe role of the surgeon in the management of GIST.
Recent progress in gastrointestinal stromal tumor's (GIST) treatment were responsible for changing GIST's natural history. Knowledge acquirement of molecular mechanism-based systemic therapy gave rise to the development of targeted antineoplastic drugs capable of reaching outcomes that had never been reached before. The introduction of imatinib in the clinical practice not only changed GIST's p...
متن کاملNursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Gastrointestinal stromal tumor (GIST), a form of soft-tissue sarcoma, is the most common noncarcinomatous tumor of the gastrointestinal tract. Despite its high incidence of recurrence, the malignant potential of GIST has been under-recognized. Advances in diagnostic technology since 2000 have led to increased diagnoses of GIST, suggesting that GIST is more common than previously suspected. Hist...
متن کاملRecent advances in the management of gastrointestinal stromal tumors
This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib therapy despite approvals by the US Food and Drug Administration and the European Medicines Agency, an...
متن کامل